Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis

BACKGROUND: Although trials suggest that anti-inflammatory approaches targeting interleukin (IL)-6 signaling can reduce cardiovascular risk, it remains unknown whether targeting IL-6 signaling could reduce risk additively to low-density lipoprotein cholesterol (LDL-C) lowering. Here, we assess inter...

Full description

Bibliographic Details
Main Authors: Burgess, S. (Author), Dichgans, M. (Author), Georgakis, M.K (Author), Malik, R. (Author)
Format: Article
Language:English
Published: American Heart Association Inc. 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 02969nam a2200229Ia 4500
001 10-1161-JAHA-121-023277
008 220420s2022 CNT 000 0 und d
020 |a 20479980 (ISSN) 
245 1 0 |a Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis 
260 0 |b American Heart Association Inc.  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1161/JAHA.121.023277 
520 3 |a BACKGROUND: Although trials suggest that anti-inflammatory approaches targeting interleukin (IL)-6 signaling can reduce cardiovascular risk, it remains unknown whether targeting IL-6 signaling could reduce risk additively to low-density lipoprotein cholesterol (LDL-C) lowering. Here, we assess interactions in associations of genetic downregulation of IL-6 signaling and LDL-C lowering with lifetime cardiovascular disease risk. METHODS AND RESULTS: Genetic scores for IL-6 signaling downregulation and LDL-C lowering were used to divide 408 225 White British individuals in UK Biobank into groups of lifelong exposure to downregulated IL-6 signaling, lower LDL-C, or both. Associations with risk of cardiovascular disease (coronary artery disease, ischemic stroke, peripheral artery disease, aortic aneurysm, vascular death) were explored in factorial Mendelian randomization. Compared with individuals with genetic IL-6 and LDL-C scores above the median, individuals with LDL-C scores lower than the median but IL-6 scores above the median had an odds ratio (OR) of 0.96 (95% CI, 0.93–0.98) for cardiovascular disease. A similar OR (0.96; 95% CI, 0.93–0.98) was estimated for individuals with genetic IL-6 scores below the median but LDL-C scores above the median. Individuals with both genetic scores lower than the median were at lower odds of cardiovascular disease (OR, 0.92; 95% CI, 0.90–0.95). There was no interaction between the 2 scores (relative excess risk attributed to interaction index, 0; synergy index, 1; P for multiplicative interaction=0.51). Genetic IL-6 score below the median was associated with lower cardiovascular disease risk across measured LDL-C strata (<100 or ≥100 mg/dL). CONCLUSIONS: Genetically downregulated IL-6 signaling and genetically lowered LDL-C are associated with additively lower lifetime risk of cardiovascular disease. Future trials should explore combined IL-6 inhibition and LDL-C lowering treatments for cardiovascular prevention. © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. 
650 0 4 |a Atherosclerosis 
650 0 4 |a Inflammation 
650 0 4 |a Interleukin-6 
650 0 4 |a Low-density lipoprotein 
650 0 4 |a Mendelian randomization 
700 1 0 |a Burgess, S.  |e author 
700 1 0 |a Dichgans, M.  |e author 
700 1 0 |a Georgakis, M.K.  |e author 
700 1 0 |a Malik, R.  |e author 
773 |t Journal of the American Heart Association